$EOLS Barclays analyst Balaji Prasad attributed this morning's surge in shares of Evolus to a Korean Times report that Medytox has received a court order allowing the company to resume sales of Meditoxin, which had been suspended since April 17. This would have provided some upside to local players like Hugel or Daewoong, but is solely applicable to the Korean market, where Evolus "is not a market participant," Prasad tells investors. Read more at: thefly.com/landingPageNews....
  • 1
1 Like